Participants
pulmonary embolism, stroke, cholestasis, intestinal malabsorption syndrome, steatorrhea
PULMONARY EMBOLISM, MYOCARDIAL INFARCTION (MI), THROMBOEMBOLIC EVENT, DEEP VEIN THROMBOSIS (DVT), STROKE, TYPE 1 DIABETES, VALVULAR HEART DISEASE, CHOLESTASIS, ATRIAL FIBRILLATION, TYPE 2 DIABETES
Individuals with type 2 diabetes were considered eligible for joining the study if their age was ranging from 18 to 65 years old, with alanine aminotransferase (ALT) levels up to 33 U/L for males and up to 25 U/L for females, albumin levels ≥ 3.5 g/dL, bilirubin up to 1.1 mg/dL [Exclusion criteria included individuals with type 1 diabetes, use of vitamin supplements except for vitamin B complex, smoking, patients requiring anti-coagulant therapy including patients with prosthetic valves, deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and valvular heart disease. Moreover, patients with previous thromboembolic events, myocardial infarction (MI), stroke, and embolization were excluded. Patients who were pregnant, breastfeeding, on hormonal therapy, contraceptive pills, glucocorticoids, thiazide diuretics, atypical antipsychotics, cholestyramine, antibiotics, coumarins, and lipid lowering agents in addition to patients who suffer from intestinal malabsorption syndrome, cholestasis or steatorrhea were excluded as well.